TY - JOUR
T1 - Mortality and exacerbation risk according to GOLD and STAR severity stages of COPD
T2 - a 5-year multicenter prospective cohort study
AU - Ogata, Hiroaki
AU - Tsubouchi, Kazuya
AU - Takano, Tomotsugu
AU - Ichiki, Katsuyuki
AU - Torii, Ryo
AU - Takata, Shohei
AU - Nakagaki, Noriaki
AU - Yoshida, Makoto
AU - Kitasato, Yasuhiko
AU - Tobino, Kazunori
AU - Harada, Eiji
AU - Wataya, Hiroshi
AU - Ishii, Hiroshi
AU - Maeyama, Takashige
AU - Kawasaki, Masayuki
AU - Fujita, Masaki
AU - Yatera, Kazuhiro
AU - Zaizen, Yoshiaki
AU - Nakanishi, Yoichi
AU - Okamoto, Isamu
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, based on percent predicted forced expiratory volume in 1 s (ppFEV1), has been widely adopted for assessment of chronic obstructive pulmonary disease (COPD) severity. However, the STaging of Airflow obstruction by Ratio (STAR) system, based on the ratio of FEV1 to forced vital capacity, was recently proposed as an alternative classification. This study aimed to compare the prognostic performance of the GOLD and STAR classifications for prediction of mortality and exacerbation risk in individuals with COPD. This 5-year prospective, multicenter cohort study enrolled 370 individuals with COPD at 29 medical centers. All-cause mortality risk across GOLD and STAR stages was evaluated with Kaplan-Meier curves and Cox proportional hazards models. The risk of moderate to severe COPD exacerbations across GOLD and STAR stages was examined with cumulative incidence function (CIF) curves and Fine and Gray models. Both classification systems showed a significant association with mortality and exacerbation risk (P < 0.01 for trend). The GOLD classification provided a better separation of Kaplan-Meier and CIF curves for advanced stages, whereas the STAR classification showed a clearer distinction between stages I and II. These associations remained consistent after multivariable adjustments. The GOLD classification was superior for prediction of prognosis in advanced COPD, whereas the STAR classification provided better differentiation in early-stage disease. These findings highlight the complementary roles of the GOLD and STAR classifications in assessment of COPD severity.
AB - The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, based on percent predicted forced expiratory volume in 1 s (ppFEV1), has been widely adopted for assessment of chronic obstructive pulmonary disease (COPD) severity. However, the STaging of Airflow obstruction by Ratio (STAR) system, based on the ratio of FEV1 to forced vital capacity, was recently proposed as an alternative classification. This study aimed to compare the prognostic performance of the GOLD and STAR classifications for prediction of mortality and exacerbation risk in individuals with COPD. This 5-year prospective, multicenter cohort study enrolled 370 individuals with COPD at 29 medical centers. All-cause mortality risk across GOLD and STAR stages was evaluated with Kaplan-Meier curves and Cox proportional hazards models. The risk of moderate to severe COPD exacerbations across GOLD and STAR stages was examined with cumulative incidence function (CIF) curves and Fine and Gray models. Both classification systems showed a significant association with mortality and exacerbation risk (P < 0.01 for trend). The GOLD classification provided a better separation of Kaplan-Meier and CIF curves for advanced stages, whereas the STAR classification showed a clearer distinction between stages I and II. These associations remained consistent after multivariable adjustments. The GOLD classification was superior for prediction of prognosis in advanced COPD, whereas the STAR classification provided better differentiation in early-stage disease. These findings highlight the complementary roles of the GOLD and STAR classifications in assessment of COPD severity.
KW - Chronic obstructive pulmonary disease
KW - Forced expiratory volume
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=105006919718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105006919718&partnerID=8YFLogxK
U2 - 10.1038/s41598-025-05033-w
DO - 10.1038/s41598-025-05033-w
M3 - Article
C2 - 40447720
AN - SCOPUS:105006919718
SN - 2045-2322
VL - 15
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 19097
ER -